Medical Devices and Equipment
Debate between Lord Evans of Rainow and Lord Hacking
Lord Hacking (Lab)
My Lords, we are back to medical matters. I beg leave to ask the Question standing in my name on the Order Paper.
Lord Evans of Rainow (Con)
My Lords, the department and NHS Supply Chain hold regular discussions with industry. There is an established process for reviewing price increase requests, which is set out in the terms of agreement of contracts. Each request is evaluated on a case-by-case basis. This Government are committed to working with healthcare manufacturers to secure value for money for taxpayers and support patients and care providers in accessing the products that they need.
Lord Hacking (Lab)
My Lords, I think I detect that the Government acknowledge the importance of the provision of healthcare products to both the NHS and its patients. I refer in particular to operated medical beds and pressure mattresses, going all the way down the line to such matters as catheters and colostomy equipment—I mention those because your Lordships may be more familiar with that area.
I have two questions. Do the Government recognise that providers of healthcare products, mostly fixed-price products, have faced and are facing colossal increased costs, to the point that there is a real prospect that some of them will no longer be able to provide their healthcare products to the National Health Service? Do the Government recognise the importance of providers of healthcare products to the National Health Service?
Lord Evans of Rainow (Con)
I thank the noble Lord for his important question and pay tribute to his expertise in such matters. This Government recognise the importance of the provision of healthcare products to the NHS and its patients. In February, the Government published their first ever medtech strategy. Supply conditions are proactively monitored and officials engage extensively with industry to identify threats to the supply of medical equipment. The department works closely with NHS England and the NHS to minimise the impact of potential supply disruptions on patient care. The department has agreed annual increases on Part IX drug tariff products used in primary care, and an exceptional price increase request mechanism exists.